The French journal of urology · 2025
French recommendations of the AFU Oncology Committee for Bladder Cancer: Update 2025.
СтатьяКлинические рекомендацииСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roumiguié Mathieu, Xylinas Evanguelos, Gabriel Pierre Etienne, Allory Yves, Audenet François, Bajeot Anne Sophie, Marcq Gautier, Léon Priscilla, Masson-Lecomte Alexandra, Neuzillet Yann, Seisen Thomas, Pradère Benjamin, Prost Doriane, Thibault Constance, Roupret Morgan
Аннотация
PURPOSE OF THIS DOCUMENT: The Oncology Committee of the French Urology Association (CCAFU) is proposing a 2025 summary of recommendations' changes for the management of bladder cancer (BCa).
METHODS: A systematic review of the literature from July 2024 to September 2025 was conducted by the CCAFU on the evolutions of diagnostic and therapeutic management of BCa evaluating the newly published references with their level of evidence.
RESULTS: On NMIBC BCa guidelines: the addition of a new recommendation to the sections "4.3. High-risk tumours" and "5.2. BCG-endovesical therapy" related to the association BCG + systemic immunotherapy. On MIBC guidelines: new recommendations to the sections "3.1.1. Neoadjuvant cisplatin-based chemotherapy" and "3.2.2. Adjuvant immunotherapy treatment" related to the perioperative combination of chemotherapy and immunotherapy.
CONCLUSION: This 2025 summary of changes of French recommendations should help physicians to stay up-to-date with recent evolutions and aim to improve the management of BCa patients.
METHODS: A systematic review of the literature from July 2024 to September 2025 was conducted by the CCAFU on the evolutions of diagnostic and therapeutic management of BCa evaluating the newly published references with their level of evidence.
RESULTS: On NMIBC BCa guidelines: the addition of a new recommendation to the sections "4.3. High-risk tumours" and "5.2. BCG-endovesical therapy" related to the association BCG + systemic immunotherapy. On MIBC guidelines: new recommendations to the sections "3.1.1. Neoadjuvant cisplatin-based chemotherapy" and "3.2.2. Adjuvant immunotherapy treatment" related to the perioperative combination of chemotherapy and immunotherapy.
CONCLUSION: This 2025 summary of changes of French recommendations should help physicians to stay up-to-date with recent evolutions and aim to improve the management of BCa patients.